DNER and lymphoma: In conclusion, our data demonstrate the in vitro and in vivo anti-lymphoma activity of the BET degrader MZ1, characterized by the ability to induce cell death and wide effects on the transcriptome of ABC DLBCL cells, providing the rationale for its further development in this disease.